Erratum: Corrigendum: Modeling dynamic interactions between pre-exposure prophylaxis interventions &treatment programs: Predicting HIV transmission &resistance (Scientific Reports (2015) 1:(185); (Doi:10.1038/srep00185));Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: Predicting HIV transmission & resistance

Scientific Reports

Volumn 1, Issue , 2011, Pages

  Supervie, Virginie ^a,d   Barrett, Meagan ^a   Kahn, James S ^b   Musuka, Godfrey ^c   Moeti, Themba Lebogang ^c   Busang, Lesogo ^c   Blower, Sally ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c African Comprehensive HIV/AIDS Partnerships   (Botswana)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BOTSWANA; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALE; MIDDLE AGED; MUTATION; PREVALENCE; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SURFACE PROPERTY; UNCERTAINTY;

ADOLESCENT; ADULT; BOTSWANA; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, STATISTICAL; MUTATION; PREVALENCE; SENSITIVITY AND SPECIFICITY; SURFACE PROPERTIES; UNCERTAINTY; YOUNG ADULT;

EID: 84859743112     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13037     Document Type: Erratum

References (49)

1. AVAC. Table of Ongoing and Completed PrEP trials. (2011).Available at http://www. avac. org/ht/d/sp/i/3507/pid/3507 (accessed on 11/07/2011).
2. Paxton, L. A., Hope, T. & Jaffe, H. W. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 370, 89-93 (2007). (Pubitemid 47033881)
3. Hillier, S. Pre-Exposure Prophylaxis: Could ItWork? Conference on Retroviruses and Opportunistic Infections (2009).
4. Grant, R. M. et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med (2010).
5. Baeten, J. & Celum, C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. 6th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abstract #MOAX0106. Rome, Italy (2011).
6. Thigpen, M. C. et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. 6th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abstract #WELBC01. Rome, Italy (2011).
7. Hurt, C. B., Eron, J. J., Jr. & Cohen, M. S. Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost? Clin Infect Dis (2011).
8. Aghokeng, A. F. et al. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS 25, 2183-2188 (2011).
9. Hamers, R. L. et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11, 750-759 (2011).
10. Masse, B. R., Boily, M. C., Dimitrov, D. & Desai, K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol 6, 5 (2009).
11. Weiss, H. A., Wasserheit, J. N., Barnabas, R. V., Hayes, R. J. & Abu-Raddad, L. J. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol 5, 8 (2008).
12. Family Health International. FHI to initiate orderly closure of FEM-PrEP. (2011).Available at Available at: http://www. fhi. org/en/Research/Projects/ FEMPrEP. htm (accessed on 11/07/2011).
13. Garcia-Lerma, J. G. et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5, e28 (2008).
14. Subbarao, S. et al. Chemoprophylaxiswith tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 194, 904-911 (2006). (Pubitemid 44454075)
15. Van Rompay, K. K. et al. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 74, 1767-1774 (2000). (Pubitemid 30434034)
16. Veazey, R. S. et al. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 11, 1293-1294 (2005). (Pubitemid 41752908)
17. Garcia-Lerma, J. G. et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2, 14ra14 (2010).
18. Smith, D. et al. Clinical utility of HIV standard genotyping among antiretroviralnaive individuals with unknown duration of infection. Clin Infect Dis 44, 456-458 (2007). (Pubitemid 46147633)
19. Verhofstede, C., Wanzeele, F. V., Van Der Gucht, B., De Cabooter, N. & Plum, J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13, 2541-2546 (1999). (Pubitemid 30038032)
20. Devereux, H. L., Youle, M., Johnson, M. A. & Loveday, C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13, F123-127 (1999). (Pubitemid 30038026)
21. Brodard, V. et al. Prevalence of detection and dynamics of selection and reversion of K65R mutation in nucleoside reverse transcriptase inhibitor-experienced patients failing an antiretroviral regimen. J Acquir Immune Defic Syndr 39, 250-253 (2005). (Pubitemid 40741126)
22. Supervie, V., Garcia-Lerma, J. G., Heneine, W. & Blower, S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA 107, 12381-12386 (2010).
23. van de Vijver, D. A., Derdelinckx, I. & Boucher, C. A. Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. J Infect Dis 199, 1310-1317 (2009).
24. Abbas, U. L., Hood, G., Wetzel, A. W. & Mellors, J. W. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP).PLoS One 6, e18165 (2011).
25. Vissers, D. C., Voeten, H. A., Nagelkerke, N. J., Habbema, J. D. & de Vlas, S. J. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One 3, e2077 (2008).
26. Abbas, U. L., Anderson, R. M. & Mellors, J. W. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2, e875 (2007).
27. Pretorius, C., Stover, J., Bollinger, L., Bacaer, N. & Williams, B. Evaluating the costeffectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 5, e13646 (2010).
28. Fiebig, E. W. et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17, 1871-1879 (2003). (Pubitemid 37070272)
29. Owen, S. M. et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol 46, 1588-1595 (2008). (Pubitemid 351657199)
30. Steen, T. W. et al. Two and a half years of routine HIV testing in Botswana. J Acquir Immune Defic Syndr 44, 484-488 (2007). (Pubitemid 46555386)
31. Mine, M., Ntsipe, T., Nkoane, T., Moyo, S. & Gaolathe, T. Evaluation of Determine and UniGold Rapid Test Kits for Serologic Screening of HIV-exposed but Uninfected Infants under 18 Months of Age in a Modified Testing Algorithm in Botswana. 18th Conference on Retroviruses and Opportunistic Infections. Abstract #Boston, USA (2011).
32. Plate, D. K. Evaluation and implementation of rapid HIV tests: the experience in 11 African countries. AIDS research and human retroviruses 23, 1491-1498 (2007).
33. UNAIDS. 2008 Report on the global AIDS epidemic. (2008. )Available at http://www. unaids. org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008- Global-report. asp (accessed on 11/07/2011).
34. National AIDS Coordinating Agency (NACA) and Central Statistics Office (CSO).2008 Botswana AIDS impact survey III (BAIS III).(2009).Available at (accessed on 11/07/2011).
35. Ministry of Health in Botswana. The Botswana annual country report on the national HIV drug resistance prevention and assessment strategy. (2008).Available at (accessed on 11/07/2011).
36. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. (2008).Available at http://www. who. int/hiv/pub/ 2008progressreport/en/index. html (accessed on 11/07/2011).
37. National AIDS Coordination Agency (NACA).HIV/AIDS in Botswana: Estimated Trends and Implications Based on Surveillance and Modeling. (October 2008).Available at (accessed on 11/07/2011).
38. Bussmann, H. et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 22, 2303-2311 (2008).
39. Doualla-Bell, F. et al. Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens. J Int AIDS Soc 12, 25 (2009).
40. Ministry of Health in Botswana. Botswana National HIV/AIDS Treatment Guidelines: 2008 version. (2008).Available at http://www. aidstar-one. com/botswana-national-hivaids-treatment-guidelines-2008-version (accessed on 11/07/2011).
41. Box, G. E. P. & Draper, N. R. Response surfaces, mixtures, and ridge analyses. 2nd ed. Hoboken, N. J. : John Wiley (2007).
42. National AIDS Coordinating Agency (NACA) and Central Statistics Office (CSO).Botswana AIDS Impact Survey II (BAIS II).(2005).Available at www. unbotswana. org. bw/. ./final-popular-report-feb06. pdf (accessed on 11/07/2011).
43. Quinn, T. C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342, 921-929 (2000). (Pubitemid 30177052)
44. Abdool Karim, S. S. & Baxter, C. Antiretroviral Prophylaxis for the Prevention of HIV Infection: Future Implementation Challenges. HIV Ther 3, 3-6 (2009).
45. Dyer, J. R. et al. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 177, 1742-1746 (1998). (Pubitemid 28243608)
46. Operskalski, E. A. et al. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol 146, 655-661 (1997). (Pubitemid 27454553)
47. Smith, R. J. & Blower, S. M. Could disease-modifying HIV vaccines cause population-level perversity? Lancet Infect Dis 4, 636-639 (2004). (Pubitemid 39296838)
48. Wawer, M. J. et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191, 1403-1409 (2005). (Pubitemid 40563350)
49. Blower, S. M. & Dowlatabadi, H. Sensitivity and uncertainty analysis of complex models of disease transmission-An HIV model, as an example. Int Stat Rev 62, 229-243 (1994).